Gonadotropin-releasing hormone agonists in the treatment of prostate cancer. - Wikidata - awgldk - TriplyDB

Gonadotropin-releasing hormone agonists in the treatment of prostate cancer.

Gonadotropin-releasing hormone agonists in the treatment of prostate cancer.

http://www.wikidata.org/entity/Q36113782

about

Evidence-based recommendations on androgen deprivation therapy for localized and advanced prostate cancer Structural characterization of the human androgen receptor ligand-binding domain complexed with EM5744, a rationally designed steroidal ligand bearing a bulky chain directed toward helix 12 Gonadotropin-releasing hormone agonists sensitize, and resensitize, prostate cancer cells to docetaxel in a p53-dependent manner Gonadotropin-releasing hormone analog structural determinants of selectivity for inhibition of cell growth: support for the concept of ligand-induced selective signaling.Increased risk of pneumonia in patients receiving gonadotropin-releasing hormone agonists for prostate cancer.Gonadotropin-releasing hormone type II antagonist induces apoptosis in MCF-7 and triple-negative MDA-MB-231 human breast cancer cells in vitro and in vivo.Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide.Luteinising hormone-releasing hormone antagonists in prostate cancer therapy.mda-7/IL-24 differentially regulates soluble and nuclear clusterin in prostate cancer.Role of gonadotropin-releasing hormone analogues in metastatic male breast cancer: results from a pooled analysis A prospective, observational grouped analysis to evaluate the effect of triptorelin on lower urinary tract symptoms in patients with advanced prostate cancer.Stepping-stones to the further advancement of androgen-deprivation therapy for prostate cancer.Role of hormonal therapy for prostate cancer: perspective from Japanese experiences.The triad of erectile dysfunction, hypogonadism and the metabolic syndrome.Effectiveness and adverse effects of hormonal therapy for prostate cancer: Japanese experience and perspective Activin receptor signaling regulates prostatic epithelial cell adhesion and viability.Intramuscular depot formulations of leuprolide acetate suppress testosterone levels below a 20 ng/dL threshold: a retrospective analysis of two Phase III studies.Degarelix: a novel gonadotropin-releasing hormone blocker for the treatment of prostate cancer.Degarelix for prostate cancer.The Influence of Androgen Deprivation Therapy on Prostate Size and Voiding Symptoms in Prostate Cancer Patients in Korea.Clinical use of GnRH agonists in canine and feline species.Blockade of testicular and adrenal androgens in prostate cancer treatment.New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists.Nuclear receptors and endobiotics glucuronidation: the good, the bad, and the UGT.Agonists of luteinizing hormone-releasing hormone in prostate cancer.Chemical castration and anti-androgens induce differential gene expression in prostate cancer.Pharmacokinetic and pharmacodynamic profile of degarelix for prostate cancer.Triptorelin for the relief of lower urinary tract symptoms in men with advanced prostate cancer: results of a prospective, observational, grouped-analysis study.Effect of triptorelin on lower urinary tract symptoms in Australian prostate cancer patients.Androgen synthesis in prostate cancer: do all roads lead to Rome?Importance of the intracrine metabolism of adrenal androgens in androgen-dependent prostate cancer.Predominant suppression of follicle-stimulating hormone β-immunoreactivity after long-term treatment of intact and castrate adult male rats with the gonadotrophin-releasing hormone agonist deslorelin A stability indicating capillary electrophoresis method for analysis of buserelin.Genetic variants associated with predisposition to prostate cancer and potential clinical implications.Effects of androgen deprivation on glycaemic control and on cardiovascular biochemical risk factors in men with advanced prostate cancer with diabetes.Partial androgen suppression consequent to increased secretion of adrenal androgens in a patient with prostate cancer treated with long-acting GnRH agonists.Andrology of male-to-female transsexuals: influence of cross-sex hormone therapy on testicular function.TSPYL Family Regulates CYP17A1 and CYP3A4 Expression: Potential Mechanism Contributing to Abiraterone Response in Metastatic Castration-Resistant Prostate Cancer.Impact of Androgen Deprivation Therapy on Volume Reduction and Lower Urinary Tract Symptoms in Patients with Prostate Cancer.Short-term buserelin administration induces apoptosis and morphological changes in adult rat testes.

P2860

Q26739738-58A34D07-EE9B-4D62-809F-6F75CC49F540 Q27647445-BB2BBB59-0D0A-4ADB-A719-00019647732B Q28537723-BD2E7852-72DC-4082-B6D2-3B7918A1749C Q33642701-803A7FF9-A99F-41FF-89C3-6761DE44BFC7 Q33817447-33ECEB47-F16A-49DD-8368-458F51B2AB17 Q34173433-85808D52-9C0F-4631-A6FD-C16362CDABB1 Q34637448-8F735050-07FE-4002-98CF-C7CCD05A92AB Q34644401-0C92B3C6-BCF0-458C-8418-8E35BEA2F93B Q35587172-788CCC9F-B326-41E6-887D-147A359D909B Q35633574-D3D57588-2980-4937-B024-61CEDF47A9E8 Q35797395-26A10745-C0EE-484A-B751-8AC1520ADFD5 Q36381291-6D0B1C2C-0070-41FB-B18E-B536154AB870 Q36450795-912FF308-B9A3-4E5D-9500-3AFCE66D3000 Q36575143-3948E4A0-AC01-4B15-8A75-756B0F3AAEA1 Q37044229-7BC1A3FF-12C4-4D49-A464-32DA2CEF3CE2 Q37133929-1A364E81-1C56-422B-A4A1-0A2A4C92949C Q37214500-02215725-A8B4-463A-8D06-00E95280736B Q37486759-C283BBE8-06A8-46E1-B37B-183269D96746 Q37488225-A6C0AD9A-42E1-45E6-A9DB-34E9F028556C Q37554004-98E81423-9243-4F6F-A9B4-9310816A552E Q37801976-60802A4D-A62F-4C49-BD49-E14F385D6024 Q37829637-62C1B5B4-8F14-4C59-B83B-99F5EC9CACD0 Q38023124-574DE75B-5059-4928-8954-AD348B5C67F7 Q38074990-4B782B01-7E5B-4D37-8552-1E3747F4FC7D Q38132229-CA025F3F-E3EB-4A74-BDB2-478271276DA4 Q38326753-BD65D278-0A18-42F4-9CA7-AEE57EC0A8C0 Q38619233-64C0D14D-F6BA-43AE-93E3-102DF3626B74 Q38658856-9692E93E-7477-473F-9F90-03A99E1707A4 Q38928284-9DC56589-CA69-4561-8CDB-D9C11308A49A Q39002780-B09C16DC-D6B2-4682-990E-D948ED16B3A3 Q40154021-04B30B35-22CE-4E4D-81C4-FD69495700BE Q41434042-5B560848-0C36-4585-ADDC-7AF2A4B0FE01 Q42919027-97406958-E8B8-4D24-8F50-FA6369318142 Q43415543-E21880D2-DA7D-40FA-ABA1-66EA70E4D140 Q43959465-D0A20FD7-7556-4DE6-BC3D-111CA0A60560 Q45662104-B386FA9E-455F-489F-AB89-17803E197B92 Q47637958-099C8870-8616-438C-9BDB-9210CD219B19 Q47659136-C9D2A205-9785-4D5D-B99A-388EDA18D185 Q48724046-3D160E9B-6F42-4D59-A0BF-DF67FC7ADC9F Q51097168-AB916C09-6A73-452F-B0F8-07805E2006D6

P2860

Gonadotropin-releasing hormone agonists in the treatment of prostate cancer.

http://www.wikidata.org/entity/Q36113782

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

Gonadotropin-releasing hormone agonists in the treatment of prostate cancer.

@ast

Gonadotropin-releasing hormone agonists in the treatment of prostate cancer.

@en

type

label

Gonadotropin-releasing hormone agonists in the treatment of prostate cancer.

@ast

Gonadotropin-releasing hormone agonists in the treatment of prostate cancer.

@en

prefLabel

Gonadotropin-releasing hormone agonists in the treatment of prostate cancer.

@ast

Gonadotropin-releasing hormone agonists in the treatment of prostate cancer.

@en

P1433

Q36113782-2CBD9966-FBF9-4552-B915-395FD083B216

P1476

Q36113782-7531729D-5A4D-40C3-8DA5-A5101AACA40E

P2093

Q36113782-19ABB306-2B78-4227-BEF0-CE67D2BD0F6D

Q36113782-3AA1C4A6-CE6A-4CA5-AFAD-507C7DD2D89B

Q36113782-5579EE5A-9774-480F-821B-EC6D382198AC

Q36113782-96ABD3B7-4BD6-423C-A608-593A7DEEFD42

Q36113782-CA682B14-70C0-40AE-ACAF-211B8487B4A7

Q36113782-D436AB31-7DC2-47BA-AEC0-230EB22ED5AB

Q36113782-DCC13FC3-BF1E-4A3C-8546-A9535BDAE59A

P304

Q36113782-60A7C36B-8D75-47C3-ADF2-D3AA9748D723

P31

Q36113782-E497DA20-CCA6-4274-AF2C-362BD653AF90

P356

Q36113782-B82D60A0-469A-47EF-8F33-59FABA0EB488

P433

Q36113782-7681847D-2133-4B4C-A951-B6A30BAE0CE7

P478

Q36113782-CA2139D1-E168-48D4-B2FE-AF5C3B5835C3

P50

Q36113782-77E8E760-6421-4745-935A-FC3C9F2855A2

P577

Q36113782-B2A090AD-2B0C-439B-93EB-3DBA50E3340F

P5875

Q36113782-FE932079-235D-4E02-A5DA-8BA029745872

P698

Q36113782-02EAB729-21CC-4370-8A90-6C7350539564

P356

P1433

Endocrine Reviews

P1476

Gonadotropin-releasing hormone agonists in the treatment of prostate cancer.

@en

P2093

Alain Bélanger

http://www.w3.org/2001/XMLSchema#string

Bernard Candas

http://www.w3.org/2001/XMLSchema#string

Claude Labrie

http://www.w3.org/2001/XMLSchema#string

Fernand Labrie

http://www.w3.org/2001/XMLSchema#string

José Gomez

http://www.w3.org/2001/XMLSchema#string

Leonello Cusan

http://www.w3.org/2001/XMLSchema#string

Van Luu-The

http://www.w3.org/2001/XMLSchema#string

P304

361-379

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1210/ER.2004-0017

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P50

P577

2005-05-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7871395

http://www.w3.org/2001/XMLSchema#string

P698

15867098

http://www.w3.org/2001/XMLSchema#string